AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 22 min read$LGND

Reardon Andrew sold $324K of LGND

Reardon Andrew (CLO & Secretary) sold 1,432 shares of LIGAND PHARMACEUTICALS INC (LGND) at $225.97 ($0.32M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Reardon Andrew
Published Jun 2, 2026, 10:22 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 2, 2026, 10:27 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$LGND
Neutral
medium confidence
Mentioned
$LGND
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LGNDNeutralLow
01

Why it matters

The disclosure provides a datapoint on insider activity but does not introduce new company fundamentals (no earnings, trial, approval, or deal).

02

Market read

Traders may treat this as a low-signal sentiment item rather than a catalyst; watch for unusual follow-on insider activity or fundamental news.

03

What to watch

The net signal depends on whether this is part of a larger scheduled program and whether other insiders are buying/selling around the same period.

Relevance 6/10Novelty 3/10Timing: Filed June 2; sale executed June 1 (open-market, 10b5-1).

Background

This is an SEC Form 4 insider transaction disclosure for Ligand Pharmaceuticals, Inc. (LGND).

Company-level read

Ticker impact

$LGNDNeutralMedium confidence
Context

SEC Form 4 shows officer Andrew Reardon sold 1,432 LGND shares in an open-market transaction under a 10b5-1 plan.

Expected impact

Likely limited/short-lived impact; any reaction is more sentiment-driven than fundamental.

Evidence & confidence

The filing is an ownership-change disclosure with no accompanying company-specific operational or financial catalyst; 10b5-1 reduces interpretive weight.

Market effects

Sector

Minimal—single-company insider transaction without new drug/clinical/regulatory information.

Regional

None expected beyond local sentiment for LGND.

Global

None.

Counterpoint

What could challenge this read

Even with 10b5-1, repeated insider selling can coincide with management’s risk/valuation view; monitor for follow-on sales outside planned windows.

Key entities

  • public_company
    LGND

    Ligand Pharmaceuticals, Inc.; officer Andrew Reardon reported an open-market sale under a 10b5-1 plan.

  • insider
    Andrew Reardon

    CLO & Secretary; sold 1,432 shares on 2026-06-01.

Read at source← All news

Related articles

AUG 8
$LGNDMed

Ligand Pharmaceuticals Incorporated Q2 2026 Earnings Call Summary

Ligand Pharmaceuticals reported Q2 2026 results and discussed its XOMA Royalty acquisition, adding 120+ assets and extending cash flow duration through 2040. Management cited 32% YoY royalty revenue growth and expects 2026 royalty revenue of $225M-$250M with cash opex halved since 2022. Ligand issued a $700M zero-coupon convertible, raised 2026 adjusted EPS guidance to $9.00-$9.50, and expects accretion from XOMA in 2H26 and 2027.

yahoo.com7 min
AUG 6
$LGNDMed

LIGAND PHARMACEUTICALS INC (LGND): Results of Operations and Financial Condition

LIGAND PHARMACEUTICALS INC (LGND) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q22026earningsrelease_ex991.htm EX-99.1 Document Ligand Reports Second Quarter 2026 Financial Results Second quarter performance driven by strong year-over-year royalty revenue growth of 32% Raises Low End of 2026 Adjusted EPS Guidance; Revenue Guidance Unchanged Confer

SEC EDGAR 8-K6 min
JUL 14
$LGNDMedAI 9/10

XOMA Royalty Announces Closing of Its Acquisition by Ligand

XOMA Royalty said Ligand Pharmaceuticals (Nasdaq: LGND) completed its acquisition of XOMA Royalty. Under the April 27 deal, XOMA shareholders received $39.00 cash per share and one non-transferable CVR per share tied to 75% of net proceeds from certain pending litigation. XOMA shares no longer trade on Nasdaq.

manilatimes.net2 min
JUL 14
$LGNDMedAI 9/10

Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets

Ligand Pharmaceuticals (Nasdaq: LGND) completed its acquisition of XOMA Royalty for $39.00 per share in cash, totaling about $739 million equity value, plus one CVR per share tied to 75% of net litigation proceeds. The deal adds seven commercial products and 100+ development assets, expanding its portfolio to 200+ royalties. Expected EPS accretion: +$0.50 (2026) and +$1.50 (2027).

manilatimes.net3 min
JUL 14
$LGNDMed

LIGAND PHARMACEUTICALS INC (LGND): Completion of Acquisition or Disposition of Assets

LIGAND PHARMACEUTICALS INC (LGND) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. 8-K LIGAND PHARMACEUTICALS INC false 0000886163 0000886163 2026-07-14 2026-07-14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest

SEC EDGAR 8-K4 min
JUL 13
$CECOMed

5 Stock Setups Where Wall Street Sees the Most Upside Right Now

The article lists five “upside” stock calls from Wall Street. JPMorgan initiated CECO Environmental (CECO) with a $130 target, citing AI data center demand and Thermon. It also targets PRM at $50. Goldman upgraded Toast (TOST) to Buy at $36. BofA raised Ligand (LGND) target to $388. Revolution Medicines (RVMD) reported Phase 3 pancreatic cancer results for daraxonrasib, with median OS 13.2 vs 6.7 months.

yahoo.com7 min